Literature DB >> 25611047

A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation.

Jason Glover1, Mark Krailo, Tanya Tello, Neyssa Marina, Katherine Janeway, Don Barkauskas, Timothy M Fan, Richard Gorlick, Chand Khanna.   

Abstract

BACKGROUND: Survival rates of patients with osteosarcoma have remained stagnant over the last thirty years. Better understanding of biology, new therapeutics, and improved biomarkers are needed. The Children's Oncology Group (COG) addressed this need by developing one of the largest osteosarcoma biorepositories ever, containing over 15,000 tumor and tissue samples from over 1,500 patients. PROCEDURE: The biology study P9851 and the banking study AOST06B1 has enrolled 1,787 patients (as of September, 2013). Clinical information was lacking on 510 patients on P9851, who were not enrolled on a concurrent therapeutic trial. The value of these specimens was diminished. The lack of statistical support available for biology projects slowed the analysis of several critical studies. The QuadW Foundation, CureSearch, and the COG formed the Childhood Sarcoma Biostatistics and Annotation Office (CSBAO) to provide the infrastructure and address these needs by linking clinically annotated patient data to archived tissue samples and to develop biostatistical support for childhood sarcoma research.
RESULTS: Originally 5.3% of samples from the 510 patients on P9851 not enrolled on a therapeutic study had full clinical annotation. The efforts of the CSBAO have linked clinical annotation to 90.8% of those specimens and provided statistical analyses to several studies that had used COG samples. As a result, 24 biology studies in osteosarcoma have been completed and published in peer-reviewed journals.
CONCLUSIONS: These samples and in-silico data are available to the research community for basic and translational science projects to improve the biological understanding and treatment of patients affected by osteosarcoma.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  banking; biology; bone; osteosarcoma; sarcoma

Mesh:

Substances:

Year:  2014        PMID: 25611047      PMCID: PMC4304398          DOI: 10.1002/pbc.25346

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  29 in total

1.  Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.

Authors:  David Ebb; Paul Meyers; Holcombe Grier; Mark Bernstein; Richard Gorlick; Steven E Lipshultz; Mark Krailo; Meenakshi Devidas; Donald A Barkauskas; Gene P Siegal; William Shay Ferguson; George Douglas Letson; Karen Marcus; Allen Goorin; Peter Beardsley; Neyssa Marina
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  Scott C Borinstein; Donald A Barkauskas; Mark Krailo; Daniel Scher; Lauren Scher; Silke Schlottmann; Bhaskar Kallakury; Paul S Dickman; Bruce R Pawel; Daniel C West; Richard B Womer; Jeffrey A Toretsky
Journal:  Cancer       Date:  2011-04-08       Impact factor: 6.860

3.  High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children's Oncology Group.

Authors:  Sadaf Altaf; Felicity Enders; Elysia Jeavons; Mark Krailo; Donald A Barkauskas; Paul Meyers; Carola Arndt
Journal:  Pediatr Blood Cancer       Date:  2013-08-17       Impact factor: 3.167

4.  Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.

Authors:  Katherine A Janeway; Donald A Barkauskas; Mark D Krailo; Paul A Meyers; Cindy L Schwartz; David H Ebb; Nita L Seibel; Holcombe E Grier; Richard Gorlick; Neyssa Marina
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

5.  Poor survival for osteosarcoma of the pelvis: a report from the Children's Oncology Group.

Authors:  Michael S Isakoff; Donald A Barkauskas; David Ebb; Carol Morris; G Douglas Letson
Journal:  Clin Orthop Relat Res       Date:  2012-02-22       Impact factor: 4.176

6.  Psychosocial and functional outcomes in long-term survivors of osteosarcoma: a comparison of limb-salvage surgery and amputation.

Authors:  Rhonda S Robert; Giulia Ottaviani; Winston W Huh; Shana Palla; Norman Jaffe
Journal:  Pediatr Blood Cancer       Date:  2010-07-01       Impact factor: 3.167

7.  Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.

Authors:  Xin-Yan Lu; Yaojuan Lu; Yi-Jue Zhao; Kim Jaeweon; Jason Kang; Li Xiao-Nan; Gouqing Ge; Rene Meyer; Laszlo Perlaky; John Hicks; Murali Chintagumpala; Wei-Wen Cai; Marc Ladanyi; Richard Gorlick; Ching C Lau; Debananda Pati; Michael Sheldon; Pulivarthi H Rao
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

Review 8.  Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.

Authors:  Richard Gorlick; Peter Anderson; Irene Andrulis; Carola Arndt; G Peter Beardsley; Mark Bernstein; Julia Bridge; Nai-Kong Cheung; Jeffrey S Dome; David Ebb; Thomas Gardner; Mark Gebhardt; Holcombe Grier; Marc Hansen; John Healey; Lee Helman; Janet Hock; Janet Houghton; Peter Houghton; Andrew Huvos; Chand Khanna; Mark Kieran; Eugenie Kleinerman; Marc Ladanyi; Ching Lau; David Malkin; Neyssa Marina; Paul Meltzer; Paul Meyers; Deborah Schofield; Cindy Schwartz; Malcolm A Smith; Jeffrey Toretsky; Maria Tsokos; Leonard Wexler; Jon Wigginton; Stephen Withrow; Mason Schoenfeldt; Barry Anderson
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

9.  The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC.

Authors:  L Ren; S H Hong; J Cassavaugh; T Osborne; A J Chou; S Y Kim; R Gorlick; S M Hewitt; C Khanna
Journal:  Oncogene       Date:  2008-12-08       Impact factor: 9.867

10.  Detectable clonal mosaicism and its relationship to aging and cancer.

Authors:  Kevin B Jacobs; Meredith Yeager; Weiyin Zhou; Sholom Wacholder; Zhaoming Wang; Benjamin Rodriguez-Santiago; Amy Hutchinson; Xiang Deng; Chenwei Liu; Marie-Josephe Horner; Michael Cullen; Caroline G Epstein; Laurie Burdett; Michael C Dean; Nilanjan Chatterjee; Joshua Sampson; Charles C Chung; Joseph Kovaks; Susan M Gapstur; Victoria L Stevens; Lauren T Teras; Mia M Gaudet; Demetrius Albanes; Stephanie J Weinstein; Jarmo Virtamo; Philip R Taylor; Neal D Freedman; Christian C Abnet; Alisa M Goldstein; Nan Hu; Kai Yu; Jian-Min Yuan; Linda Liao; Ti Ding; You-Lin Qiao; Yu-Tang Gao; Woon-Puay Koh; Yong-Bing Xiang; Ze-Zhong Tang; Jin-Hu Fan; Melinda C Aldrich; Christopher Amos; William J Blot; Cathryn H Bock; Elizabeth M Gillanders; Curtis C Harris; Christopher A Haiman; Brian E Henderson; Laurence N Kolonel; Loic Le Marchand; Lorna H McNeill; Benjamin A Rybicki; Ann G Schwartz; Lisa B Signorello; Margaret R Spitz; John K Wiencke; Margaret Wrensch; Xifeng Wu; Krista A Zanetti; Regina G Ziegler; Jonine D Figueroa; Montserrat Garcia-Closas; Nuria Malats; Gaelle Marenne; Ludmila Prokunina-Olsson; Dalsu Baris; Molly Schwenn; Alison Johnson; Maria Teresa Landi; Lynn Goldin; Dario Consonni; Pier Alberto Bertazzi; Melissa Rotunno; Preetha Rajaraman; Ulrika Andersson; Laura E Beane Freeman; Christine D Berg; Julie E Buring; Mary A Butler; Tania Carreon; Maria Feychting; Anders Ahlbom; J Michael Gaziano; Graham G Giles; Goran Hallmans; Susan E Hankinson; Patricia Hartge; Roger Henriksson; Peter D Inskip; Christoffer Johansen; Annelie Landgren; Roberta McKean-Cowdin; Dominique S Michaud; Beatrice S Melin; Ulrike Peters; Avima M Ruder; Howard D Sesso; Gianluca Severi; Xiao-Ou Shu; Kala Visvanathan; Emily White; Alicja Wolk; Anne Zeleniuch-Jacquotte; Wei Zheng; Debra T Silverman; Manolis Kogevinas; Juan R Gonzalez; Olaya Villa; Donghui Li; Eric J Duell; Harvey A Risch; Sara H Olson; Charles Kooperberg; Brian M Wolpin; Li Jiao; Manal Hassan; William Wheeler; Alan A Arslan; H Bas Bueno-de-Mesquita; Charles S Fuchs; Steven Gallinger; Myron D Gross; Elizabeth A Holly; Alison P Klein; Andrea LaCroix; Margaret T Mandelson; Gloria Petersen; Marie-Christine Boutron-Ruault; Paige M Bracci; Federico Canzian; Kenneth Chang; Michelle Cotterchio; Edward L Giovannucci; Michael Goggins; Judith A Hoffman Bolton; Mazda Jenab; Kay-Tee Khaw; Vittorio Krogh; Robert C Kurtz; Robert R McWilliams; Julie B Mendelsohn; Kari G Rabe; Elio Riboli; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Joanne W Elena; Herbert Yu; Laufey Amundadottir; Rachael Z Stolzenberg-Solomon; Peter Kraft; Fredrick Schumacher; Daniel Stram; Sharon A Savage; Lisa Mirabello; Irene L Andrulis; Jay S Wunder; Ana Patiño García; Luis Sierrasesúmaga; Donald A Barkauskas; Richard G Gorlick; Mark Purdue; Wong-Ho Chow; Lee E Moore; Kendra L Schwartz; Faith G Davis; Ann W Hsing; Sonja I Berndt; Amanda Black; Nicolas Wentzensen; Louise A Brinton; Jolanta Lissowska; Beata Peplonska; Katherine A McGlynn; Michael B Cook; Barry I Graubard; Christian P Kratz; Mark H Greene; Ralph L Erickson; David J Hunter; Gilles Thomas; Robert N Hoover; Francisco X Real; Joseph F Fraumeni; Neil E Caporaso; Margaret Tucker; Nathaniel Rothman; Luis A Pérez-Jurado; Stephen J Chanock
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

View more
  14 in total

Review 1.  Future directions in the treatment of osteosarcoma.

Authors:  Michael W Bishop; Katherine A Janeway; Richard Gorlick
Journal:  Curr Opin Pediatr       Date:  2016-02       Impact factor: 2.856

2.  Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials.

Authors:  K A Rejniak; M C Lloyd; D R Reed; M M Bui
Journal:  Med Hypotheses       Date:  2015-06-24       Impact factor: 1.538

Review 3.  Advancing therapy for osteosarcoma.

Authors:  Jonathan Gill; Richard Gorlick
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

Review 4.  Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.

Authors:  Pooja Hingorani; Katherine Janeway; Brian D Crompton; Cigall Kadoch; Crystal L Mackall; Javed Khan; Jack F Shern; Joshua Schiffman; Lisa Mirabello; Sharon A Savage; Marc Ladanyi; Paul Meltzer; Carol J Bult; Peter C Adamson; Philip J Lupo; Rajen Mody; Steven G DuBois; D Williams Parsons; Chand Khanna; Ching Lau; Douglas S Hawkins; R Lor Randall; Malcolm Smith; Poul H Sorensen; Sharon E Plon; Stephen X Skapek; Stephen Lessnick; Richard Gorlick; Damon R Reed
Journal:  Cancer Genet       Date:  2016-04-05

5.  MicroRNA-128 inhibits EMT of human osteosarcoma cells by directly targeting integrin α2.

Authors:  Xinsheng Liu; Zhiyong Liang; Kehai Gao; Huazhuang Li; Guangzong Zhao; Shantao Wang; Jun Fang
Journal:  Tumour Biol       Date:  2015-12-24

Review 6.  Osteosarcoma: Accelerating Progress Makes for a Hopeful Future.

Authors:  Amanda J Saraf; Joelle M Fenger; Ryan D Roberts
Journal:  Front Oncol       Date:  2018-01-26       Impact factor: 6.244

Review 7.  Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy.

Authors:  Sarah E Ballatori; Philip W Hinds
Journal:  Signal Transduct Target Ther       Date:  2016-03-25

8.  Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation.

Authors:  Jason Glover; Tsz-Kwong Man; Donald A Barkauskas; David Hall; Tanya Tello; Mary Beth Sullivan; Richard Gorlick; Katherine Janeway; Holcombe Grier; Ching Lau; Jeffrey A Toretsky; Scott C Borinstein; Chand Khanna; Timothy M Fan
Journal:  PLoS One       Date:  2017-07-21       Impact factor: 3.240

9.  Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation.

Authors:  Dapeng Yu; Shuisheng Zhang; Alei Feng; Deguo Xu; Qingshan Zhu; Yantao Mao; Yi Zhao; Yajuan Lv; Cuiping Han; Rujun Liu; Yuan Tian
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

10.  Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

Authors:  Neyssa M Marina; Sigbjørn Smeland; Stefan S Bielack; Mark Bernstein; Gordana Jovic; Mark D Krailo; Jane M Hook; Carola Arndt; Henk van den Berg; Bernadette Brennan; Bénédicte Brichard; Ken L B Brown; Trude Butterfass-Bahloul; Gabriele Calaminus; Heike E Daldrup-Link; Mikael Eriksson; Mark C Gebhardt; Hans Gelderblom; Joachim Gerss; Robert Goldsby; Allen Goorin; Richard Gorlick; Holcombe E Grier; Juliet P Hale; Kirsten Sundby Hall; Jendrik Hardes; Douglas S Hawkins; Knut Helmke; Pancras C W Hogendoorn; Michael S Isakoff; Katherine A Janeway; Heribert Jürgens; Leo Kager; Thomas Kühne; Ching C Lau; Patrick J Leavey; Stephen L Lessnick; Leo Mascarenhas; Paul A Meyers; Hubert Mottl; Michaela Nathrath; Zsuzsanna Papai; R Lor Randall; Peter Reichardt; Marleen Renard; Akmal Ahmed Safwat; Cindy L Schwartz; Michael C G Stevens; Sandra J Strauss; Lisa Teot; Mathias Werner; Matthew R Sydes; Jeremy S Whelan
Journal:  Lancet Oncol       Date:  2016-08-25       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.